Early access program (EAP)

An early access program (EAP) allows patients with serious or life-threatening conditions to access investigational therapies prior to full regulatory approval.

What is an early access program (EAP)?

An EAP, also known as compassionate use or expanded access, is a mechanism that provides eligible patients with access to investigational medicines outside of clinical trials. These programs are typically used when no satisfactory alternatives exist and are governed by strict regulatory requirements.

Why are EAPs important in pharmaceutical development?

EAPs offer patients potential benefit while allowing companies to collect additional safety or real-world data. They also build goodwill with the clinical and patient community, support pre-launch engagement, and may inform future regulatory and access strategies. Managing EAPs effectively requires close coordination with Regulatory and Medical Affairs teams.

Linked Resource here?
No spam. Just the latest releases and tips, interesting articles, and exclusive interviews in your inbox every week.
Read about our privacy policy.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.